Amgen's Sjögren's drug reduces disease activity in trial

Amgen's Sjögren's drug trial reducing disease activity creates a positive news flow for the company's pipeline and could attract buying interest in the stock in the short term. On the technical side, the price is trading above the SMA20 and SMA50, the RSI is at 60, not yet in overbought territory, and the MACD is above the signal line, presenting a positive outlook. The 1.5% 24-hour upward momentum is likely to be confirmed by the news. However, the impact of drug trial news is usually short-lived, and additional clinical data or the approval process should be followed for a sustained rally. Therefore, although I see the direction as upward, I maintain a moderate level of confidence.

The news headline pertains to Amgen and is not directly related to GOOGL's fundamentals; therefore, its impact on the stock is likely to be limited. Technical indicators present a moderately positive picture: the price is above the SMA20 and SMA50, the RSI at 59 is far from overbought territory, and the MACD is above its signal line. The 24-hour gain of 2.7% indicates strong short-term momentum, but the news catalyst is weak. Thus, while the direction is considered neutral, the current technical outlook supports a slight upward bias. Confidence is kept low due to the news's irrelevance.